accountNEW YORK (TheStreet) -- Obagi Medical Products (Nasdaq:OMPI) has been downgraded by TheStreet Ratings from buy to hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Obagi Medical Products Inc. Stock Downgraded (OMPI)
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account